Clinical Trial Update: Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating Abraxane with bevacizumab biosimilar in patients with recurrent, platinum-resistant epithelial ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• Bevacizumab biosimilar (Bevacizumab)

Snippet

Sponsor: Shandong University | Conditions: Objective Response Rate | Phase 2 | Status: UNKNOWN